8-K Announcements
6Material company update
Jan 26, 2026·SEC
Material company update
Jan 23, 2026·SEC
Material company update
Aug 7, 2025·SEC
Daxor Corporation(DXR)Earnings, Financials & Key Ratios
DXR•NASDAQ
$10.53
5.7× P/E·Price updated Jul 6, 2026
AboutDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.Show more
- Revenue$503K-76.4%
- EBITDA$9M+346.3%
- Net Income$9M+1609.7%
- EPS (Diluted)1.84+1572.7%
- Gross Margin37.49%-62.5%
- EBITDA Margin1824.65%+1789.1%
- Operating Margin1824.65%+6156.8%
- Net Margin1821.48%+7136.9%
- ROE22.45%+1361.1%
DXR Price & Volume
Daxor Corporation (DXR) stock price & volume — 10-year historical chart
Loading chart...
Investment Portfolio Gains Mask Core Operational Stagnation
Investment Thesis • Updated 2025Q4
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Investment Portfolio Market Sensitivity
Key Thesis Takeaways
- Daxor Corporation presents a unique investment profile where the core medical device business, centered on the BVA-100 platform, struggles to achieve commercial scale as evidenced by an 81.0% year-over-year revenue decline in 2025Q4.
- The company's financial health is currently tethered to a volatile investment portfolio rather than recurring diagnostic kit sales, creating a disconnect between reported net income and operational cash flow.
- Investors should monitor the sustainability of this funding model, as the reliance on non-operating investment gains to offset persistent operational losses may prove precarious in shifting market conditions.
Verdict Logic
the company's reliance on non-operating investment income to mask a core business that generated only $131.8K in 2025Q4 revenue suggests significant long-term commercial viability risks.
DXR Growth Metrics
Daxor Corporation (DXR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM132.18%
Profit CAGR
10 Years-
5 Years-
3 Years20.98%
TTM77.81%
EPS CAGR
10 Years-
5 Years-
3 Years45.29%
TTM125.39%
Return on Capital
10 Years4.88%
5 Years13.62%
3 Years8.35%
Last Year22.29%
Peers Comparison
Key metrics vs top competitors for Daxor Corporation (DXR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.53 | $53.06M | 5.72 | -76.38% | 1821.48% | 22.45% | — | |
| $129.75 | $5.74B | -6.41 | -34.61% | -35.89% | -28.27% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $22.58 | $11.66B | -12.90 | 5.72% | -9.7% | -16.5% | — | |
| $155.54 | $56.35B | 26.68 | 8.23% | 5.33% | 4.54% | — | |
| $432.83 | $153.29B | 55.00 | 20.51% | 28.15% | 16.89% | — |
Compare DXR vs Peers
Daxor Corporation (DXR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DXR SEC Filings & Documents
Daxor Corporation (DXR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when DXR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DXR Frequently Asked Questions
Daxor Corporation (DXR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Daxor Corporation's revenue?
Daxor Corporation (DXR) reported $0.9M in revenue for fiscal year 2025. This represents a 67% decrease from $2.8M in 1996.
How fast is Daxor Corporation growing?
Daxor Corporation (DXR) saw revenue decline by 76.4% over the past year.
Is DXR profitable?
Yes, Daxor Corporation (DXR) is profitable, generating $9.7M in net income for fiscal year 2025 (1821.5% net margin).
Dividend & Returns
What is DXR's return on equity?
Daxor Corporation (DXR) has a return on equity (ROE) of 22.5%. This is excellent, indicating efficient use of shareholder capital.
What is Daxor Corporation's free cash flow?
Daxor Corporation (DXR) had negative free cash flow of $1.2M in fiscal year 2025, likely due to heavy capital investments.